EARTH CITY, Mo.–(BUSINESS WIRE)–Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the release of “Patient-First Approach Maximizes Therapeutic Benefits of Humatin™ for Treatment of Intestinal Amebiasis.”
“Optime Care’s patient-first drug management program and how our team helps to optimize the benefits of Humatin for patients with acute and chronic intestinal amebiasis,” says Donovan Quill, president and CEO, Optime Care, and author of the paper. “Readers will gain insight into how our singular approach can ensure care continuity across the entire patient journey with robust communication to yield rich data that clinicians can use to make more informed decisions and improve the overall patient experience.”
Intestinal amebiasis is a parasitic infection of the intestines caused by a protozoan Entamoeba histolytica that can affect anyone, although it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions. People become infected by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan. Of those infected, approximately 10-20% become sick.
The Optime Care team, including care coordinators, pharmacists, nurses and other specialists, focuses on the disease state, patient community and therapy. Optime offers a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of intestinal amebiasis. This approach enables patients to become more engaged and take ownership, which leads to a stronger partnership and better patient care.
Quill concludes, “Our patient-first approach is critical for transcending the limitations of the standard specialty pharmacy and hub service provider, which too often rely on technology solutions that fail to address human needs and variability.”